Pharmacokinetic Interaction Between Prasugrel and Ritonavir in Healthy Volunteers

Basic and Clinical Pharmacology and Toxicology

Volumn 112, Issue 2, 2013, Pages 132-137

  Ancrenaz, Virginie ^a   Déglon, Julien ^b   Samer, Caroline ^a,c   Staub, Christian ^b   Dayer, Pierre ^a,c   Daali, Youssef ^a,c   Desmeules, Jules ^a,c  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY CENTER OF LEGAL MEDICINE   (Switzerland)

^c UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A; PRASUGREL; RITONAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRIED BLOOD SPOT TESTING; DRUG EFFECT; ENZYME ACTIVITY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; HALF-LIFE; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDAZOLAM; PIPERAZINES; RITONAVIR; THIOPHENES; TIME FACTORS; YOUNG ADULT;

EID: 84872151682     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2012.00932.x     Document Type: Article

References (26)

1. Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 2005;111:3366-73.
2. Rehmel JL, Eckstein JA, Farid NA, Heim JB, Kasper SC, Kurihara A et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos 2006;34:600-7.
3. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998;38:389-430.
4. Turpeinen M, Raunio H, Pelkonen O. The functional role of CYP2B6 in human drug metabolism: substrates and inhibitors in vitro, in vivo and in silico. Curr Drug Metab 2006;7:705-14.
5. Farid NA, Payne CD, Small DS, Winters KJ, Ernest CS 2nd, Brandt JT et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007;81:735-41.
6. Farid NA, Small DS, Payne CD, Jakubowski JA, Brandt JT, Li YG et al. Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects. Pharmacotherapy 2008;28:1483-94.
7. Farid NA, Jakubowski JA, Payne CD, Li YG, Jin Y, Ernest IC et al. Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects. Curr Med Res Opin 2009;25:1821-9.
8. Daali Y, Ancrenaz V, Bosilkovska M, Dayer P, Desmeules J. Ritonavir inhibits the two main prasugrel bioactivation pathways in vitro: a potential drug-drug interaction in HIV patients. Metabolism 2011;60:1584-9.
9. Knox TA, Oleson L, von Moltke LL, Kaufman RC, Wanke CA, Greenblatt DJ. Ritonavir greatly impairs CYP3A activity in HIV infection with chronic viral hepatitis. J Acquir Immune Defic Syndr 2008;49:358-68.
10. Mathias AA, West S, Hui J, Kearney BP. Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure. Clin Pharmacol Ther 2009;85:64-70.
11. Yeh RF, Gaver VE, Patterson KB, Rezk NL, Baxter-Meheux F, Blake MJ et al. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 2006;42:52-60.
12. Hesse LM, von Moltke LL, Shader RI, Greenblatt DJ. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. Drug Metab Dispos 2001;29:100-2.
13. Barfield M, Spooner N, Lad R, Parry S, Fowles S. Application of dried blood spots combined with HPLC-MS/MS for the quantification of acetaminophen in toxicokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci 2008;870:32-7.
14. Beaudette P, Bateman KP. Discovery stage pharmacokinetics using dried blood spots. J Chromatogr B Analyt Technol Biomed Life Sci 2004;809:153-8.
15. Clark GT, Haynes JJ, Bayliss MA, Burrows L. Utilization of DBS within drug discovery: development of a serial microsampling pharmacokinetic study in mice. Bioanalysis 2010;2:1477-88.
16. EMA. Draft Guidelines on Validation of Bioanalytical Methods. Available: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf (last accessed on 28 March 2012).
17. Jerdi MC, Daali Y, Oestreicher MK, Cherkaoui S, Dayer P. A simplified analytical method for a phenotyping cocktail of major CYP450 biotransformation routes. J Pharm Biomed Anal 2004;35:1203-12.
18. Greenblatt DJ, Peters DE, Oleson LE, Harmatz JS, MacNab MW, Berkowitz N et al. Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4, 4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase. Br J Clin Pharmacol 2009;68:920-7.
19. Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997;44:190-4.
20. Chien JY, Lucksiri A, Ernest CS 2nd, Gorski JC, Wrighton SA, Hall SD. Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole. Drug Metab Dispos 2006;34:1208-19.
21. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;55:481-5.
22. Sekar V, Spinosa-Guzman S, De Paepe E, Stevens T, Tomaka F, De Pauw M et al. Pharmacokinetics of multiple-dose darunavir in combination with low-dose ritonavir in individuals with mild-to-moderate hepatic impairment. Clin Pharmacokinet 2010;49:343-50.
23. Dixit V, Hariparsad N, Li F, Desai P, Thummel KE, Unadkat JD. Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab Dispos 2007;35:1853-9.
24. Wyen C, Fuhr U, Frank D, Aarnoutse RE, Klaassen T, Lazar A et al. Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. Clin Pharmacol Ther 2008;84:75-82.
25. Brandt JT, Payne CD, Wiviott SD, Weerakkody G, Farid NA, Small DS et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007;153:66.e9-16.
26. Payne CD, Li YG, Small DS, Ernest CS 2nd, Farid NA, Jakubowski JA et al. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol 2007;50:555-62.